加载中
NASDAQFinancial ServicesFinancial - Conglomerates
最新数据
US$10.19
US$0.00 · 0.00%
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
收盘时
US$10.19
US$0.00 · 0.00%
盘中时间采用ET。市场数据可能有所延迟。
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
日内区间
当前US$10.19
52周区间
当前US$10.19
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
85
深度低估
情绪
55
多空交织
风险
8
低风险
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
日内区间
当前US$10.19
52周区间
当前US$10.19
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 |
|---|---|---|
| 销售、一般及管理费用 | 130.05万 USD | 15.17万 USD |
| 营业费用 | 130.05万 USD | 15.17万 USD |
| 利息收入 | 493.38万 USD | — |
| 营业利润 | −130.05万 USD | −15.17万 USD |
| 净利润 | 418.71万 USD | −15.17万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
